Chemotherapy for high-risk retinoblastoma after eye removal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 interventional study aims to evaluate the effectiveness of three cycles of chemotherapy (CEV) in patients with Stage I enucleated retinoblastoma. Participants will receive chemotherapy on a monthly basis and will be monitored for a duration of 60 months to assess treatment outcomes. The study is designed to provide insights into the potential benefits of adjuvant chemotherapy in preventing recurrence of retinoblastoma after surgical removal of the affected eye.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to provide written informed consent and comply with study assessments for the full duration of the study.
* Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.
* Received enucleation in the study eye.
* Monocular retinoblastoma.

Exclusion Criteria:

* Any previous disease in the study eye.
* Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
* History of chemical intervention for retinoblastoma in the study eye.

Where it's running

• Zhongshan Ophthalmic Center, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Huasheng Yang, M.D, PHD
• Email: yanghs64@126.com
• Phone: +8620-87331539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

  This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai, China · NCT06972602

• Linking RB1 genetic changes to eye tumors and metastasis

  We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.

  Recruiting University of Washington · Seattle, Washington · NCT06725173

• Treatment for advanced retinoblastoma using a chemoplaque

  This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.

  Recruiting at 2 sites Phase 2 Targeted Therapy Technologies, LLC · New York, New York and 1 other locations · NCT06679634

• New treatment for children with hard-to-treat retinoblastoma

  This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai · NCT06424301

• Understanding the incidence and outcomes of trilateral retinoblastoma

  This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06367530

• Collecting and analyzing eye fluid from children with retinoblastoma

  This study is trying to see if collecting eye fluid from children with retinoblastoma can help find important markers for better treatment and understanding of the disease.

  Recruiting at 9 sites Children's Hospital Los Angeles · Phoenix, Arizona and 8 other locations · NCT04959097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.